MDxHealth SA, an Irvine-based maker of noninvasive prostate tests, today reported early results for the fourth quarter and full year.
The company anticipates fourth quarter and full year revenues of approximately $30.5 million and $109 million, representing a 23% and 21% increase, respectively. MDxHealth also issued 2026 revenue guidance of $137 million to $140 million.
“We are confident that the strength of our sales channel coupled with our expanded menu offering to our urology customer base will continue to drive sustainable growth,” Chief Executive Michael McGarrity said in a statement.
Shares fell 2.8% to $3.17 and a $163 million market cap.
